AR043110A1 - Sal de heparina de bajo peso molecular con trietanolamina util como agente terapeutico-antitrombotico de administracion topica, procedimientos para preparar dichas sales, proceso para la eliminacion de la higroscopicidad de la sal de heparina, composiciones farmaceuticas para uso topico en terapia a - Google Patents

Sal de heparina de bajo peso molecular con trietanolamina util como agente terapeutico-antitrombotico de administracion topica, procedimientos para preparar dichas sales, proceso para la eliminacion de la higroscopicidad de la sal de heparina, composiciones farmaceuticas para uso topico en terapia a

Info

Publication number
AR043110A1
AR043110A1 ARP040100347A ARP040100347A AR043110A1 AR 043110 A1 AR043110 A1 AR 043110A1 AR P040100347 A ARP040100347 A AR P040100347A AR P040100347 A ARP040100347 A AR P040100347A AR 043110 A1 AR043110 A1 AR 043110A1
Authority
AR
Argentina
Prior art keywords
salt
triethanolamine
useful
low molecular
therapeutic
Prior art date
Application number
ARP040100347A
Other languages
English (en)
Original Assignee
Syntex Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Sa filed Critical Syntex Sa
Priority to ARP040100347A priority Critical patent/AR043110A1/es
Priority to US11/024,082 priority patent/US20050234015A1/en
Priority to JP2004379644A priority patent/JP4607575B2/ja
Priority to CA2491398A priority patent/CA2491398C/en
Priority to EP05250081A priority patent/EP1561760B1/en
Priority to DE602005011189T priority patent/DE602005011189D1/de
Priority to AT05250081T priority patent/ATE415424T1/de
Priority to CNB2005100091529A priority patent/CN100564397C/zh
Publication of AR043110A1 publication Critical patent/AR043110A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)

Abstract

Sal de heparina de bajo peso molecular con trietanolamina útil como agente terapéutico-antitrombótico de administración tópica, que comprende al menos 60% de su masa total con un peso molecular inferior a 8000 Da y un peso molecular promedio comprendido entre 4000 y 6000 Da, presentando además dicha sal un contenido de azufre orgánico de entre 6,1 y 7,5 % en peso (teórico 6,8 % en peso) y un contenido de trietanolamina de entre 42,6 y 52,1 % en peso (teórico 47,4 % en peso). Se describen además procedimientos para preparar dichas sales, proceso para la eliminación de la higroscopicidad de la sal de heparina, composiciones farmacéuticas para uso tópico en terapia antitrombótica y usos en dichas terapias.
ARP040100347A 2004-02-04 2004-02-04 Sal de heparina de bajo peso molecular con trietanolamina util como agente terapeutico-antitrombotico de administracion topica, procedimientos para preparar dichas sales, proceso para la eliminacion de la higroscopicidad de la sal de heparina, composiciones farmaceuticas para uso topico en terapia a AR043110A1 (es)

Priority Applications (8)

Application Number Priority Date Filing Date Title
ARP040100347A AR043110A1 (es) 2004-02-04 2004-02-04 Sal de heparina de bajo peso molecular con trietanolamina util como agente terapeutico-antitrombotico de administracion topica, procedimientos para preparar dichas sales, proceso para la eliminacion de la higroscopicidad de la sal de heparina, composiciones farmaceuticas para uso topico en terapia a
US11/024,082 US20050234015A1 (en) 2004-02-04 2004-12-28 Low molecular weight heparin salt with triethanolamine useful as therapeutic-antitrombotic agent of local delivery, procedures for preparing them, process for elimination of hygroscopicity of heparin salt, pharmaceutical compositions for local use in antithrombotic therapy and uses therein
JP2004379644A JP4607575B2 (ja) 2004-02-04 2004-12-28 局所的送達の治療用抗血栓剤として有用なトリエタノールアミンを伴う低分子量ヘパリン塩、それらの調製方法、ヘパリン塩の吸湿性を除去するためのプロセス、抗血栓療法における局所的使用のための薬学組成物及びそれにおける使用
CA2491398A CA2491398C (en) 2004-02-04 2005-01-04 Processes for preparing triethanolamine salts of low molecular weight heparin and their use in topical creams for antithrombotic therapy
EP05250081A EP1561760B1 (en) 2004-02-04 2005-01-10 Low molecular weight heparin salt with triethanolamine
DE602005011189T DE602005011189D1 (de) 2004-02-04 2005-01-10 Salz von Heparin mit niedrigem Molekulargewicht mit Triethanolamin
AT05250081T ATE415424T1 (de) 2004-02-04 2005-01-10 Salz von heparin mit niedrigem molekulargewicht mit triethanolamin
CNB2005100091529A CN100564397C (zh) 2004-02-04 2005-02-04 用作局部给药的抗血栓形成治疗剂的低分子量肝素三乙醇胺盐其制法和用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP040100347A AR043110A1 (es) 2004-02-04 2004-02-04 Sal de heparina de bajo peso molecular con trietanolamina util como agente terapeutico-antitrombotico de administracion topica, procedimientos para preparar dichas sales, proceso para la eliminacion de la higroscopicidad de la sal de heparina, composiciones farmaceuticas para uso topico en terapia a

Publications (1)

Publication Number Publication Date
AR043110A1 true AR043110A1 (es) 2005-07-20

Family

ID=34658432

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100347A AR043110A1 (es) 2004-02-04 2004-02-04 Sal de heparina de bajo peso molecular con trietanolamina util como agente terapeutico-antitrombotico de administracion topica, procedimientos para preparar dichas sales, proceso para la eliminacion de la higroscopicidad de la sal de heparina, composiciones farmaceuticas para uso topico en terapia a

Country Status (8)

Country Link
US (1) US20050234015A1 (es)
EP (1) EP1561760B1 (es)
JP (1) JP4607575B2 (es)
CN (1) CN100564397C (es)
AR (1) AR043110A1 (es)
AT (1) ATE415424T1 (es)
CA (1) CA2491398C (es)
DE (1) DE602005011189D1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101735336B (zh) * 2009-11-06 2012-07-18 深圳海王药业有限公司 低聚岩藻糖化糖胺聚糖及其制备方法
CN101724086B (zh) 2009-11-25 2012-09-26 深圳海王药业有限公司 低聚凤梨参糖胺聚糖及其制备方法
EP3144325B1 (en) * 2010-09-14 2020-11-04 University Of Miyazaki High purity heparin and production method therefor
CN102746421B (zh) * 2012-05-23 2014-03-12 杭州龙扬生物科技有限公司 粗品肝素钠的除杂工艺
RU2539380C1 (ru) * 2014-01-14 2015-01-20 Александр Ливиевич Ураков Отбеливатель кровоподтеков
CN104188902B (zh) * 2014-08-25 2017-03-29 深圳市天道医药有限公司 一种高稳定性达肝素钠注射液的生产工艺
CN104479047B (zh) * 2014-12-20 2016-08-17 山东绅联生物科技有限公司 一种中品肝素钠的提取方法
RU2573382C1 (ru) * 2015-01-16 2016-01-20 Александр Ливиевич Ураков Средство для внутрикожного отбеливания синяка
RU2639283C1 (ru) * 2016-12-12 2017-12-20 Общество с ограниченной ответственностью "Институт термологии" Способ обесцвечивания синяка под глазом
RU2639485C1 (ru) * 2017-01-23 2017-12-21 Общество с ограниченной ответственностью "Институт термологии" Средство для прижизненного отбеливания кожи в области синяков под глазами
CN111019014A (zh) * 2019-11-22 2020-04-17 苏州二叶制药有限公司 一种那曲肝素钙的制备工艺
CN114773530B (zh) * 2022-03-29 2023-05-12 河南驼人医疗器械研究院有限公司 一种具有抗凝血功能的聚合物乳液及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3020220A1 (de) * 1980-05-28 1981-12-03 Theodor Prof. Dr. 4400 Münster Eckert Organische salze des heparin, der heparinoide, ihre herstellung und sie enthaltende arzneimittel
DE3331009A1 (de) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
FR2584728B1 (fr) * 1985-07-12 1987-11-20 Choay Sa Procede de sulfatation de glycosaminoglycanes et de leurs fragments
AR243204A1 (es) * 1986-11-21 1993-07-30 Ajorca Sa Un metodo para la depolimerizacion quimica de polisacaridos.
DE3744119A1 (de) * 1987-12-24 1989-07-06 Basf Ag Verwendung von polysulfatierten heparinen
GB8826448D0 (en) * 1988-11-11 1988-12-14 Thrombosis Res Inst Improvements in/relating to organic compounds
US6458383B2 (en) * 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
DE10141106A1 (de) * 2001-08-22 2003-03-13 Aventis Pharma Gmbh Verwendung von Heparinoid-Derivaten zur Behandlung und Diagnose von mit Heparinoiden behandelbaren Erkrankungen
US20040072796A1 (en) * 2002-04-18 2004-04-15 Embury Stephen H. Method and composition for preventing pain in sickle cell patients

Also Published As

Publication number Publication date
EP1561760A3 (en) 2007-03-28
EP1561760A2 (en) 2005-08-10
US20050234015A1 (en) 2005-10-20
DE602005011189D1 (de) 2009-01-08
ATE415424T1 (de) 2008-12-15
EP1561760B1 (en) 2008-11-26
JP4607575B2 (ja) 2011-01-05
CA2491398C (en) 2011-04-12
JP2005220347A (ja) 2005-08-18
CA2491398A1 (en) 2005-08-04
CN100564397C (zh) 2009-12-02
CN1651470A (zh) 2005-08-10

Similar Documents

Publication Publication Date Title
AR043110A1 (es) Sal de heparina de bajo peso molecular con trietanolamina util como agente terapeutico-antitrombotico de administracion topica, procedimientos para preparar dichas sales, proceso para la eliminacion de la higroscopicidad de la sal de heparina, composiciones farmaceuticas para uso topico en terapia a
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
CY1115825T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν λεβετιρακεταμη και διαδικασια παρασκευης τους
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
SI1933809T1 (sl) Sestavki za mazalno dajanje
TW200727903A (en) Stable pharmaceutical compositions of 5, 10 methylenetetrahydrofolate
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
CL2010000606A1 (es) Uso de derivados de eritropoyetina en la preparacion de un medicamento util para proteger, mantener, mejorar o recuperar la viabilidad de celulas que responden a eritropoyetina en condiciones anomalas que afectan las celulas, tejidos u organos asociados; derivados de eritropoyetinas y composicion que las comprende (divisional de la solicitud 3188-2001).
MY160074A (en) Protopanaxadiol-type ginsenoside compositions and uses thereof
DK1331927T3 (da) Topisk komposition der indeholder mindst et D-vitamin eller en D-vitamin analog og mindst et kosttikosteroid
RS51185B (sr) Kompozicije za vaginalnu primenu
BR112018013979A2 (pt) composições em gel para liberação transdérmica para maximizar as concentrações de fármacos no estrato córneo e no soro e métodos de uso dos mesmos
WO2007143607A3 (en) Method of treating atrophic vaginitis
BRPI0504445A (pt) composição de trombina e processo para a sua preparação
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
BRPI0519280A2 (pt) composto, composiÇço farmacÊutica e uso de um composto
BG107463A (en) Clear aqueous anaesthetic composition
BR112017026287A2 (pt) composições de hidroxipropil beta-ciclodextrina e métodos
BRPI0707488B8 (pt) método para a produção de uma composição de epoprostenol, composição farmacêutica e solução estável
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
BR0312365A (pt) Meio de cultura autólogo de células-mães progenitoras autólogas humanas, métodos para a preparação do mesmo e de uma composição de células-mães progenitoras autólogas humanas e para a obtenção de células-mães progenitoras musculares autólogas humanas, emprego de um meio de cultura autólogo de células-mães progenitoras autólogas humanas, procedimento para a obtenção de células-mães progenitoras musculares autólogas humanas e procedimento terapêutico de cardiomioplastia celular autóloga, composição enriquecida com células-mães progenitoras musculares autólogas humanas e composição farmacêutica
BR112015010256A2 (pt) meio para cultivar, preservar e administrar células regenerativas
WO2016196950A1 (en) Olivamine-induced improvement in endothelial cells viability and function
BR112022003046A8 (pt) Conjugado de il-15, seu método de preparo e seus usos, bem como composição farmacêutica e método in vitro de expansão de uma ou mais das populações de células t

Legal Events

Date Code Title Description
FG Grant, registration